Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 4 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Breast 2Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Antineoplastic Agents × Breast × Clear all
NCT04004910 2022-03-24

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Immunicom Inc

Phase 1/2 Unknown
170 enrolled
Breast

Breast Neoplasms

NCT03591276 2020-10-23

KEYDOX

Shaare Zedek Medical Center

Phase 1/2 Recruiting
15 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡